During the past decade, Peninsula & South Eastern Haematology and Oncology Group conducted 41 clinical trials. In the 10-year time frame, 41 clinical trials started and 14 clinical trials were completed, i.e. on average, 34.1% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 9 clinical trials were completed. i.e. 37.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Peninsula & South Eastern Haematology and Oncology Group" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Eucure (Beijing) Biopharma Co., Ltd" with 3 trials sponsored, "Genentech, Inc." with 3 trials sponsored, "Pfizer" with 3 trials sponsored and "Arcus Biosciences, Inc." with 3 trials sponsored. Other sponsors include 25 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Peninsula & South Eastern Haematology and Oncology Group" #1 collaborator was "AstraZeneca" with 4 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Atridia Pty Ltd." with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Peninsula & South Eastern Haematology and Oncology Group" are "Breast Cancer" (6 trials), "Solid Tumor" (5 trials), "Colorectal Cancer" (3 trials), "Non-Small Cell Lung Cancer" (3 trials) and "Advanced Cancer" (2 trials). Many other conditions were trialed in "Peninsula & South Eastern Haematology and Oncology Group" in a lesser frequency.

Most popular intervention types in "Peninsula & South Eastern Haematology and Oncology Group" are "Drug" (48 trials), "Biological" (2 trials), "Other" (2 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Cisplatin" (4 trials), "Pembrolizumab" (4 trials), "Atezolizumab" (3 trials) and "Carboplatin" (3 trials). Other intervention names were less common.

The vast majority of trials in "Peninsula & South Eastern Haematology and Oncology Group" are 43 trials for "All" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "Peninsula & South Eastern Haematology and Oncology Group". undefined are not yet recruiting, 17 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Peninsula & South Eastern Haematology and Oncology Group, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Peninsula & South Eastern Haematology and Oncology Group, 22 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".